A prospective, controlled, randomized, open-label, single-center study confirmed the efficacy and safety of using the enterosorbent polymethylsiloxane polyhydrate (trade name – "Enterosgel") in the complex treatment of non-infectious diseases accompanied by diarrhea.

 Materials and Methods

The study involved 169 patients with varying degrees of diarrhea severity, hospitalized at the 3rd Central Military Clinical Hospital named after A. A. Vishnevsky of the Ministry of Defense of Russia.

All patients received conventional therapy. They were randomly divided into three groups:

Group 1 (62 patients): Received "Enterosgel" at the standard dose (1 tablespoon 3 times a day between meals).

Group 2 (56 patients): Received dioctahedral smectite.

Group 3 (51 patients): Did not receive enterosorbents.

Patients in the first group included individuals with antibiotic-associated diarrhea, irritable bowel syndrome with diarrhea, ulcerative colitis, diverticular disease, chronic pancreatitis with exocrine insufficiency, and enteropathy caused by non-steroidal anti-inflammatory drugs.

The main parameters assessed were stool frequency (number of bowel movements per day) and duration of inpatient treatment (in days).

 Results and Conclusions

The inclusion of "Enterosgel" in the conventional therapy for non-infectious diarrhea, regardless of its origin, demonstrated the ability to reduce the duration of inpatient treatment and accelerate the normalization of stool frequency.

The efficacy of "Enterosgel" was comparable to that of dioctahedral smectite.

The maximum effect from the use of "Enterosgel" was observed in patients with antibiotic-associated diarrhea and irritable bowel syndrome with diarrhea.

Full Article:For detailed familiarization with the article, as well as the complete data and tables, please follow the link to the full article: Full Article